SCHEMBL148918

SCHEMBL148918

O=C1OCCN1c1cccc2c1[nH]c1ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 2/20 0.42
KIF11 P52732 5/20 0.41
TDP1 Q9NUW8 2/20 0.40
POLB P06746 1/20 0.40
KDM4E B2RXH2 3/20 0.38
MEN1 O00255 3/20 0.38
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 3/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PARP1 P09874 2/20 0.37
CYP1A2 P05177 2/20 0.37
LMNA P02545 1/20 0.37
GPR3 P46089 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
PARP15 Q460N3 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL149469 0.77 SCN9A (0.45) TNKSKIF11TDP1POLBKDM4E
SCHEMBL8308960 0.76 IDH1 (0.46) TNKSTDP1POLBKDM4EMEN1
SCHEMBL147379 0.76 KIF11 (0.42) TNKSKIF11TDP1POLBKDM4E
SCHEMBL146694 0.74 KDM4E (0.53) KIF11TDP1POLBKDM4EMEN1
SCHEMBL19127710 0.71 KMT2A (0.40) TNKSTDP1KDM4EMEN1ALDH1A1
SCHEMBL20887126 0.71 HSD17B10 (0.50) KIF11POLBKDM4EMEN1ALDH1A1
SCHEMBL29056463 0.71 KIF11 (0.49) KIF11POLBKDM4EMEN1ALDH1A1
SCHEMBL138181 0.71 KEAP1 (0.44) TNKSKDM4EMEN1KMT2AL3MBTL1
SCHEMBL19915264 0.70 HSD17B10 (0.51) KIF11KDM4EALDH1A1HSD17B10HPGD
SCHEMBL28568514 0.70 TLR9 (0.52) TNKSKIF11TDP1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 TNKS 421/4885KIF11 4119/4885TDP1 1220/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 TNKS 421/4885KIF11 4119/4885TDP1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.